Overview
Cytochroma has four product candidates targeting
the CKD market. CTAP101 Capsules is targeted as a treatment
for vitamin D insufficiency. CTA018
Injection and CTAP201 Injection are both targeted as treatments
for SHPT and are intended to address different segments of
the overall market. The phosphate management products
target hyperphosphatemia with the goal of improving the control
of SHPT.
Last
updated on July 2009
*MTPC
will co-develop and co-commercialize CTA018 with Cytochroma
in the U.S.,
and has an exclusive royalty-bearing license
in Asia.
|
about
us